Skip to main content

Advertisement

SpringerLink
Log in

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

There is an acute unmet need to develop novel treatment regimens in the perioperative setting since many patients with muscle-invasive bladder cancer (MIBC) are not eligible for the current standard of care (SOC) neoadjuvant treatment with cisplatin-based chemotherapy. The introduction of immune checkpoint inhibitors (ICIs), both as monotherapy and in combination regimens with other ICIs, chemotherapy, or targeted drugs, may provide safe and clinically effective treatment options that could revolutionize current standard of care. In the neoadjuvant setting, compelling data from phase II clinical trials suggests that single-agent immunotherapy, as well as dual-checkpoint blockade, may emerge as reasonable alternatives to traditional cisplatin-based chemotherapy. Prospective studies combining ICIs with chemotherapy or with antibody-drug conjugates have also demonstrated robust outcomes. However, these studies are not yet practice changing and data from larger randomized studies are needed to confirm this benefit. In the adjuvant setting, nivolumab is the FDA-approved treatment based on a disease-free survival benefit relative to placebo in a randomized trial. However, it will be important to confirm an overall survival benefit of this treatment and to better identify patients who need additional adjuvant treatment based on novel biomarker data. The treatment of muscle-invasive bladder cancer is moving toward the individualization of treatment options based on specific tumor and patient characteristics and away from the one-size-fits-all approach that has dominated this space for the last couple of decades. Emerging biomarker data, such as with ctDNA, suggests that immunotherapy may confer greater benefit to selected patients. Identifying who those patients are will be of paramount importance since additional treatments always come with additional toxicities. On the other hand, the more favorable toxicity profiles of certain immunotherapy-based regimens may make them superior options for some patients who would otherwise be unable to tolerate other systemic regimens. In the near future, it is likely that subsets of patients with MIBC will be receiving treatments with predominantly immunotherapy-based regimens while many patients may still be treated with regimens containing a cisplatin-based chemotherapy backbone. Currently ongoing clinical trials will help to better define patient populations optimized for each treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–904. https://doi.org/10.1007/s00345-019-02984-4. (In eng).

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708. (In eng).

    Article  PubMed  Google Scholar 

  3. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. Jama. 2020;324(19):1980–91. https://doi.org/10.1001/jama.2020.17598. (In eng).

    Article  CAS  PubMed  Google Scholar 

  4. Lobo N, Shariat SF, Guo CC, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020;6(4):653–63. https://doi.org/10.1016/j.euf.2019.09.003. (In eng).

    Article  PubMed  Google Scholar 

  5. • Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. https://doi.org/10.1056/NEJMoa022148. This phase III trial established neoadjuvant methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) as a standard of care prior to radical cystectomy by demonstrating superior pathologic complete response and median overall survival rates in comparison to radical cystectomy alone. (Ing eng)

    Article  CAS  PubMed  Google Scholar 

  6. Neoadjuvant chemotherapy in invasive bladder cancer. update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202–5. https://doi.org/10.1016/j.eururo.2005.04.006. (discussion 205-6. (In eng)).

    Article  Google Scholar 

  7. Benkhadra R, Nayfeh T, Patibandla NSK, et al. Methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) versus gemcitabine, and cisplatin (GC) as neoadjuvant chemotherapy in muscle-invasive bladder cancer, a systematic review and meta-analysis. J Clin Oncol. 2021;39(15_suppl):e16522–e16522. https://doi.org/10.1200/JCO.2021.39.15_suppl.e16522.

    Article  Google Scholar 

  8. Pfister C, Gravis G, Fléchon A, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol. 2021;79(2):214–21. https://doi.org/10.1016/j.eururo.2020.08.024. (In eng).

    Article  CAS  PubMed  Google Scholar 

  9. van de Putte EE, Mertens LS, Meijer RP, et al. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J Urol. 2016;34(2):157–62. https://doi.org/10.1007/s00345-015-1636-y. (In eng).

    Article  CAS  PubMed  Google Scholar 

  10. Wu T, Wu Y, Chen S, et al. Curative effect and survival assessment comparing gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant therapy for bladder cancer: a systematic review and meta-analysis. Frontiers in Oncology 2021;11 (Systematic Review) (In English). https://doi.org/10.3389/fonc.2021.678896.

  11. Niedersüss-Beke D, Puntus T, Kunit T, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer. Oncology. 2017;93(1):36–42. https://doi.org/10.1159/000463389.

    Article  CAS  PubMed  Google Scholar 

  12. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8. https://doi.org/10.1200/jco.2011.34.8433. (In eng).

    Article  PubMed  Google Scholar 

  13. Bamias A, Tzannis K, Harshman LC, et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol. 2018;29(2):361–9. https://doi.org/10.1093/annonc/mdx692.

    Article  CAS  PubMed  Google Scholar 

  14. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211–4. https://doi.org/10.1016/S1470-2045(10)70275-8.

    Article  PubMed  Google Scholar 

  15. Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54. https://doi.org/10.1016/j.eururo.2013.08.033. (In eng).

    Article  CAS  PubMed  Google Scholar 

  16. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012;23(3):695–700. https://doi.org/10.1093/annonc/mdr354. (In eng).

    Article  CAS  PubMed  Google Scholar 

  17. Lehmann J, Retz M, Wiemers C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol. 2005;23(22):4963–74. https://doi.org/10.1200/jco.2005.11.094. (In eng).

    Article  CAS  PubMed  Google Scholar 

  18. Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011;29(25):3443–9. https://doi.org/10.1200/jco.2010.34.4028. (In eng).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76–86. https://doi.org/10.1016/s1470-2045(14)71160-x. (In eng).

    Article  PubMed  Google Scholar 

  20. Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268–77. https://doi.org/10.1016/S0140-6736(20)30415-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. •• Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102–14. https://doi.org/10.1056/NEJMoa2034442. The CheckMate 274 trial was first to demonstrate disease free survival benefit with adjuvant immunotherapy and introduced nivolumab as a new standard of care for treating residual disease following radical cystectomy. (In eng)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–42 (In eng).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7–H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499–505. https://doi.org/10.1002/cncr.22588. (In eng).

    Article  CAS  PubMed  Google Scholar 

  24. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7–H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173–82. https://doi.org/10.1007/s00262-006-0266-z. (In eng).

    Article  CAS  PubMed  Google Scholar 

  25. •• Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm. Phase II Study J Clin Oncol. 2018;36(34):3353–60. https://doi.org/10.1200/jco.18.01148. The PURE-01 trial marked the introduction of immunotherapy as a safe and effective neoadjuvant alternative to chemotherapy in cisplatin-ineligible patients. (In eng)

    Article  CAS  PubMed  Google Scholar 

  26. •• Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706–14. https://doi.org/10.1038/s41591-019-0628-7. The phase II ABACUS trial furthered the introduction of immunotherapy to the neoadjuvant space by demonstrating robust responses to atezolizumab in this setting. (In eng)

    Article  CAS  PubMed  Google Scholar 

  27. Szabados B, Rodriguez-Vida A, Durán I, et al. Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from the ABACUS Trial. Eur Urol Oncol. 2021;4(3):456–63. https://doi.org/10.1016/j.euo.2020.11.010. (In eng).

    Article  PubMed  Google Scholar 

  28. Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212–22. https://doi.org/10.1016/j.eururo.2022.04.013. (In eng).

    Article  CAS  PubMed  Google Scholar 

  29. Natesan DV, Zhang L, Oh DY, et al. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). J Clin Oncol. 2021;39(15_suppl):e16510–e16510. https://doi.org/10.1200/JCO.2021.39.15_suppl.e16510.

    Article  Google Scholar 

  30. Martinez Chanza N, Carnot A, Barthélémy P, et al. Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial. J Clin Oncol. 2022;40(16_suppl):4517–4517. https://doi.org/10.1200/JCO.2022.40.16_suppl.4517.

    Article  Google Scholar 

  31. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. https://doi.org/10.1136/esmoopen-2020-001079. (In eng).

    Article  PubMed  PubMed Central  Google Scholar 

  32. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86. https://doi.org/10.1016/s0140-6736(20)32714-8. (In eng).

    Article  CAS  PubMed  Google Scholar 

  33. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836. (In eng).

    Article  CAS  PubMed  Google Scholar 

  34. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020;6(11):e204564. https://doi.org/10.1001/jamaoncol.2020.4564. (In eng).

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sharma P, Siefker-Radtke A, de Braud F, et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J Clin Oncol. 2019;37(19):1608–16. https://doi.org/10.1200/jco.19.00538. (In eng).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. • Van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839–44. https://doi.org/10.1038/s41591-020-1085-z. The NABUCCO trial was one of the first studies to investigate the efficacy of dual-checkpoint inhibitor therapy with ipilimumab and nivolumab as neoadjuvant treatment in MIBC.

    Article  CAS  PubMed  Google Scholar 

  37. • Grande E, Guerrero F, Puente J, et al. DUTRENEO Trial: a randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. J Clin Oncol. 2020;38(15_suppl):5012–5012. https://doi.org/10.1200/JCO.2020.38.15_suppl.5012. The DUTRENEO trial demonstrated the safety and efficacy of durvalumab/tremelimumab combination in a biomarker-selected cohort.

    Article  Google Scholar 

  38. Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020;26(12):1845–51. https://doi.org/10.1038/s41591-020-1086-y. (In eng).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Vey N, Karlin L, Sadot-Lebouvier S, et al. A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget. 2018;9(25):17675–88. https://doi.org/10.18632/oncotarget.24832. (In eng).

    Article  PubMed  PubMed Central  Google Scholar 

  40. Grivas P, Yin J, Koshkin VS, et al. PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2021;39(15_suppl):4518–4518. https://doi.org/10.1200/JCO.2021.39.15_suppl.4518.

    Article  Google Scholar 

  41. • Gupta S, Sonpavde G, Weight CJ, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol. 2020;38(6):439–439. https://doi.org/10.1200/JCO.2020.38.6_suppl.439. Results from the BLASST-1 trial suggest that the incorporation of immunotherapy into standard chemotherapy regimens can yield robust responses but may be associated with additional toxicities to the side effect profile seen with either therapy alone.

    Article  Google Scholar 

  42. Funt SA, Lattanzi M, Whiting K, et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J Clin Oncol. 2022;40(12):1312–22. https://doi.org/10.1200/jco.21.01485.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cathomas R, Rothschild S, Hayoz S, et al. Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): primary analysis of the single arm phase II trial SAKK 06/17. J Clin Oncol. 2022;40(16_suppl):4515–4515. https://doi.org/10.1200/JCO.2022.40.16_suppl.4515.

    Article  Google Scholar 

  44. • Rose TL, Harrison MR, Deal AM, et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J Clin Oncol. 2021;39(28):3140–8. https://doi.org/10.1200/jco.21.01003. The GU 14-188 study demonstrated that combination immunotherapy and chemotherapy have comparable efficacy in both cisplatin-eligible and cisplatin-ineligible patients. (In eng)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Balar AV, Milowsky MI, O’Donnell PH, et al. Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4504–4504. https://doi.org/10.1200/JCO.2021.39.15_suppl.4504.

    Article  Google Scholar 

  46. Vazquez-Estevez S, Fernandez-Calvo O, Bonfill-Abella T, et al. Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: an interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4). J Clin Oncol. 2022;40(16_suppl):4588–4588. https://doi.org/10.1200/JCO.2022.40.16_suppl.4588.

    Article  Google Scholar 

  47. Petrylak DP, Flaig TW, Mar N, et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. J Clin Oncol. 2022;40(16_suppl):4582–4582. https://doi.org/10.1200/JCO.2022.40.16_suppl.4582.

    Article  Google Scholar 

  48. Rodriguez-Moreno JF, Sevillano E, Fenor MD, et al. Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial. Journal of Clinical Oncology. 2019;37(7_suppl):TPS503–TPS503. https://doi.org/10.1200/JCO.2019.37.7_suppl.TPS503.

    Article  Google Scholar 

  49. Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–85. https://doi.org/10.1200/JCO.20.03489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Flaig TW, Tangen CM, Daneshmand S, et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021;27(9):2435–41. https://doi.org/10.1158/1078-0432.Ccr-20-2409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. •• Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525–37. https://doi.org/10.1016/s1470-2045(21)00004-8. The IMvigor010 trial demonstrated a disease-free survival advantage amongst patients with residual disease who are ctDNA positive, introducing ctDNA as a potentially relevant biomarker in the adjuvant setting that needs further investigation. (In eng)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Apolo AB, Rosenberg JE, Kim WY, et al. Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation. J Clin Oncol. 2019;37(7_suppl):TPS504–TPS504. https://doi.org/10.1200/JCO.2019.37.7_suppl.TPS504.

    Article  Google Scholar 

Download references

Funding

This research received no external funding.

Author information

Authors and Affiliations

  1. Internal Medicine, University of California, Davis, Sacramento, CA, 95817, USA

    Amisha Singh MD & Appledene S. Osbourne MD

  2. Division of Hematology and Oncology, Department of Medicine, Helen Diller Family Cancer Center, University of California San Francisco, 550 16th Street, Office 6811, Box 3211, San Francisco, CA, 94158, USA

    Vadim S. Koshkin MD

Authors
  1. Amisha Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Appledene S. Osbourne MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vadim S. Koshkin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.S., A.O., and V.K.: writing, review, and editing. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Vadim S. Koshkin MD.

Ethics declarations

Conflict of Interest

Vadim S. Koshkin reports serving in a consulting or advisory role for AstraZeneca, Clovis, Janssen, Pfizer, EMD Serono, Seagen, Astellas, Dendreon, Guidepoint, GLG and receiving institutional research funding from Endocyte/Novartis, Nektar, Clovis, Janssen and Taiho, all unrelated to the current manuscript. Amisha Singh and Appledene S. Osbourne declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, A., Osbourne, A.S. & Koshkin, V.S. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer. Curr. Treat. Options in Oncol. 24, 1213–1230 (2023). https://doi.org/10.1007/s11864-023-01113-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-023-01113-z

Keywords

Search

Navigation